Advanced Science (Feb 2024)

Transgelin Promotes Glioblastoma Stem Cell Hypoxic Responses and Maintenance Through p53 Acetylation

  • Huan Li,
  • Chao Song,
  • Yang Zhang,
  • Guohao Liu,
  • Hailong Mi,
  • Yachao Li,
  • Zhiye Chen,
  • Xiaoyu Ma,
  • Po Zhang,
  • Lidong Cheng,
  • Peng Peng,
  • Hongtao Zhu,
  • Zirong Chen,
  • Minhai Dong,
  • Sui Chen,
  • Hao Meng,
  • QunGen Xiao,
  • Honglian Li,
  • Qiulian Wu,
  • Baofeng Wang,
  • Suojun Zhang,
  • Kai Shu,
  • Feng Wan,
  • Dongsheng Guo,
  • Wenchao Zhou,
  • Lin Zhou,
  • Feng Mao,
  • Jeremy N. Rich,
  • Xingjiang Yu

DOI
https://doi.org/10.1002/advs.202305620
Journal volume & issue
Vol. 11, no. 7
pp. n/a – n/a

Abstract

Read online

Abstract Glioblastoma (GBM) is a lethal cancer characterized by hypervascularity and necrosis associated with hypoxia. Here, it is found that hypoxia preferentially induces the actin‐binding protein, Transgelin (TAGLN), in GBM stem cells (GSCs). Mechanistically, TAGLN regulates HIF1α transcription and stabilizes HDAC2 to deacetylate p53 and maintain GSC self‐renewal. To translate these findings into preclinical therapeutic paradigm, it is found that sodium valproate (VPA) is a specific inhibitor of TAGLN/HDAC2 function, with augmented efficacy when combined with natural borneol (NB) in vivo. Thus, TAGLN promotes cancer stem cell survival in hypoxia and informs a novel therapeutic paradigm.

Keywords